Zentek Ltd. (NASDAQ:ZTEK) Short Interest Down 25.1% in February

Zentek Ltd. (NASDAQ:ZTEK) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 148,000 shares, a drop of 25.1% from the February 13th total of 197,500 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 45,800 shares, the short-interest ratio is currently 3.2 days.

Zentek Trading Down 0.0 %

Zentek stock opened at $0.92 on Tuesday. The company has a quick ratio of 1.48, a current ratio of 1.83 and a debt-to-equity ratio of 0.01. Zentek has a 12 month low of $0.50 and a 12 month high of $1.34. The company’s fifty day simple moving average is $1.05 and its 200-day simple moving average is $0.95. The stock has a market cap of $95.97 million, a P/E ratio of -13.14 and a beta of 1.30.

Zentek (NASDAQ:ZTEK) last issued its earnings results on Wednesday, February 12th. The company reported ($0.01) earnings per share for the quarter. Zentek had a negative return on equity of 58.13% and a negative net margin of 16,555.32%.

Hedge Funds Weigh In On Zentek

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZTEK. Two Sigma Securities LLC acquired a new position in shares of Zentek during the 4th quarter worth $31,000. Anson Funds Management LP acquired a new stake in shares of Zentek in the 4th quarter valued at $145,000. Finally, Scotia Capital Inc. boosted its holdings in Zentek by 5.7% in the fourth quarter. Scotia Capital Inc. now owns 958,771 shares of the company’s stock worth $867,000 after purchasing an additional 51,744 shares in the last quarter. Institutional investors own 0.77% of the company’s stock.

Zentek Company Profile

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.